Third pharmaceuticals firm picks Goldman

Goldman Sachs has racked up its third pharmaceuticals deal in weeks after working on a $2.5bn (€2bn) US transaction which follows two European deals worth $19bn last month.

Gilead Sciences, a US drug manufacturer for life-threatening infectious diseases, has agreed to acquire rival Myogen, which makes medicines for cardiovascular diseases.

WSJ Logo
Venture Debt Firms Tilt Toward Mature CompaniesExternal link

Venture Debt Firms Tilt Toward Mature Companies